Loading...
XNAS
EXAS
Market cap10bUSD
Jul 10, Last price  
53.32USD
1D
3.31%
1Q
26.45%
Jan 2017
314.00%
IPO
274.98%
Name

Exact Sciences Corp

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
3.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.01%
Rev. gr., 5y
25.78%
Revenues
2.76b
+10.37%
4,250,0004,750,0002,935,000-867,0004,758,0005,344,0004,163,0004,144,0004,144,0001,798,00039,437,00099,376,000265,989,000454,462,000876,293,0001,491,391,0001,767,087,0002,084,279,0002,499,766,0002,758,867,000
Net income
-1.03b
L+403.97%
-14,520,000-12,915,000-11,959,000-9,741,000-9,089,000-11,556,000-28,675,000-52,421,000-46,514,000-100,048,000-157,803,000-167,211,000-114,397,000-175,149,000-83,993,000-848,533,000-595,625,000-623,506,000-204,149,000-1,028,857,000
CFO
211m
+34.86%
-15,982,000-12,154,000-8,767,000-7,904,000-12,640,000-13,478,000-27,824,000-44,155,000-39,295,000-80,912,000-134,017,000-130,066,000-71,724,000-69,325,000-115,010,000136,482,000-102,236,000-223,559,000156,119,000210,536,000
Earnings
Jul 29, 2025

Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
URL
https://www.exactsciences.com/
IPO date
Jan 30, 2001
Employees
6,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,758,867
10.37%
2,499,766
19.93%
2,084,279
17.95%
Cost of revenue
2,947,310
2,700,430
2,551,127
Unusual Expense (Income)
NOPBT
(188,443)
(200,664)
(466,848)
NOPBT Margin
Operating Taxes
7,304
2,403
(9,064)
Tax Rate
NOPAT
(195,747)
(203,067)
(457,784)
Net income
(1,028,857)
403.97%
(204,149)
-67.26%
(623,506)
4.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,227
59,885
32,015
BB yield
-0.30%
-0.45%
-0.37%
Debt
Debt current
276,558
79,379
28,366
Long-term debt
2,662,738
2,665,795
2,600,904
Deferred revenue
(488,262)
Other long-term liabilities
315,503
335,982
352,459
Net debt
1,901,270
1,967,530
1,949,716
Cash flow
Cash from operating activities
210,536
156,119
(223,559)
CAPEX
(135,989)
(124,190)
(214,462)
Cash from investing activities
(442,155)
49,679
74,066
Cash from financing activities
231,874
159,766
76,485
FCF
(242,078)
(193,370)
(555,070)
Balance
Cash
1,038,026
777,644
632,057
Long term investments
47,497
Excess cash
900,083
652,656
575,340
Stockholders' equity
(4,497,119)
(3,465,932)
(3,268,482)
Invested Capital
9,969,629
9,501,944
8,622,712
ROIC
ROCE
EV
Common stock shares outstanding
184,197
180,144
176,351
Price
56.19
-24.05%
73.98
49.42%
49.51
-36.39%
Market cap
10,350,029
-22.34%
13,327,053
52.64%
8,731,138
-34.53%
EV
12,251,299
15,294,583
10,680,854
EBITDA
26,416
5,944
(269,290)
EV/EBITDA
463.78
2,573.11
Interest
31,974
24,421
19,634
Interest/NOPBT